Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | -0.00% | +4.95% | +9.02% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.02% | 19.77M | |
+4.67% | 111B | |
+11.01% | 105B | |
-12.31% | 22.34B | |
-3.90% | 21.93B | |
-6.08% | 18.59B | |
-36.52% | 18.12B | |
-9.92% | 16.96B | |
+2.80% | 13.7B | |
+36.06% | 12.45B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar